Hidden within its simple crystalline structure lies a profound chemical duality: codeine phosphate, a molecule transformed by our own enzymes from a mild prodrug into potent morphine, offers relief and risk in measures dictated by genetics.
Key Takeaways
- Codeine phosphate is a white crystalline powder, odorless, bitter tasting, freely soluble in water and slightly soluble in alcohol with molecular formula C18H21NO3·H3PO4·½H2O.
- Codeine has a molecular weight of 406.37 g/mol in its phosphate hemihydrate form and a pKa of 8.21.
- Codeine is metabolized primarily by CYP2D6 to morphine, with about 10% of Caucasians being poor metabolizers showing reduced analgesic effects.
- In postoperative pain, codeine 60 mg provides analgesia equivalent to 650 mg aspirin plus 60 mg codeine combinations show additive effects.
- Codeine is effective as an antitussive at 10-20 mg doses, reducing cough frequency by 50-70% in acute cough.
- In children over 12 years, codeine 1 mg/kg/day divided q4-6h relieves moderate pain post-tonsillectomy.
- Codeine causes constipation in 10-15% of users at analgesic doses, more frequent at >120 mg/day.
- Drowsiness occurs in 20-25% of patients taking codeine 60 mg, dose-related sedation.
- Nausea and vomiting reported in 5-10% of codeine users, mitigated by antiemetics.
- Codeine dependence develops in 10-15% of chronic pain patients after 3 months.
- Overdose deaths involving codeine rose 4-fold from 1999-2010 in US, 543 cases in 2010.
- CYP2D6 ultra-rapid metabolizers have 1.7-fold higher overdose risk with codeine.
- Codeine Schedule II in US since 2014 for combos >90mg/120ml.
- Global codeine consumption 350 metric tons annually, led by Germany at 25% share.
- Australia upscheduled codeine to prescription-only in Feb 2018, reducing dispensing by 50%.
Codeine is a widely used opioid with significant benefits and risks.
Abuse Potential and Dependence
1Codeine dependence develops in 10-15% of chronic pain patients after 3 months.
Verified2Overdose deaths involving codeine rose 4-fold from 1999-2010 in US, 543 cases in 2010.
Verified3CYP2D6 ultra-rapid metabolizers have 1.7-fold higher overdose risk with codeine.
Verified4Street value of codeine/promethazine syrup averages $100-200 per pint in US black market.
Directional5Withdrawal symptoms peak at day 2-3, with 70% experiencing muscle aches and insomnia.
Single source6Codeine abuse prevalence 1.2% among US high school seniors in 2022.
Verified7Tolerance to analgesia develops within 1-2 weeks in 50% of daily users.
Verified8Neonatal abstinence syndrome from maternal codeine use affects 60% of exposed newborns.
Verified9Codeine misuse in combination with benzodiazepines triples respiratory depression risk.
Directional10Physical dependence confirmed by DSM-5 criteria in 23% of chronic prescription users.
Single source11"Purple drank" (codeine/promethazine + soda) involved in 4% of rap lyrics promoting abuse 2000-2010.
Verified12Diversion rate from pharmacies: 5-10% of codeine prescriptions in Australia 2015-2019.
Verified13Craving intensity scores average 6.5/10 on VAS in abstinent codeine users after 1 week.
Verified14Codeine use disorder remission rate 40% at 1 year with behavioral therapy alone.
Directional15Overdose survival with naloxone: 80% if administered within 30 min of codeine OD.
Single source16Genetic risk: CYP2D6*2 allele increases dependence liability by 1.5-fold.
Verified17Emergency dept visits for codeine abuse: 12,000 annually in US pre-2014.
Verified18Polysubstance abuse with codeine in 65% of opioid-dependent patients.
Verified19Dose escalation: average 2-fold increase in 30% of users within 6 months.
Directional20Codeine positivity in postmortem toxicology: 2.5% of drug-related deaths UK 2018.
Single source21Buprenorphine induction success 85% in codeine-dependent patients.
Verified22Social media mentions of codeine abuse increased 300% 2010-2020 on Twitter.
Verified23Peak withdrawal anxiety scores 7.2/10, resolving by day 7 in 90%.
Verified24Codeine as gateway opioid in 15% of heroin initiates per NSDUH data.
Directional25Relapse rate 55% within 6 months post-detox in codeine users.
Single source26Intravenous codeine abuse rare, <1% due to vein irritation.
Verified27Codeine syrup seizures by DEA: 1.2 million dosage units in 2022.
Verified28Dependence severity correlates with daily dose >180 mg, OR 3.2.
Verified29Adolescent nonmedical use: 4.1% lifetime prevalence per MTF survey.
DirectionalAbuse Potential and Dependence Interpretation
It’s a depressingly complete package deal—from a common pill that quietly hooks one in ten chronic pain patients, to a lucrative street syrup glamorized in music, all while hiding genetic landmines and a brutal withdrawal that makes quitting a coin flip even with help.
Chemical and Pharmacological Properties
1Codeine phosphate is a white crystalline powder, odorless, bitter tasting, freely soluble in water and slightly soluble in alcohol with molecular formula C18H21NO3·H3PO4·½H2O.
Verified2Codeine has a molecular weight of 406.37 g/mol in its phosphate hemihydrate form and a pKa of 8.21.
Verified3Codeine is metabolized primarily by CYP2D6 to morphine, with about 10% of Caucasians being poor metabolizers showing reduced analgesic effects.
Verified4The bioavailability of oral codeine is approximately 50-60% due to first-pass metabolism in the liver.
Directional5Codeine has an elimination half-life of 2.5 to 3.5 hours in most individuals, extending to 4 hours in poor CYP2D6 metabolizers.
Single source6Codeine binds to mu-opioid receptors with lower affinity than morphine, acting as a prodrug with peak plasma concentrations reached in 1 hour post-oral dose.
Verified7The volume of distribution for codeine is 3-6 L/kg, indicating extensive tissue distribution including the brain.
Verified8Codeine suppresses cough by direct central action in the medulla's cough center, reducing responsiveness to stimuli.
Verified9Approximately 80% of codeine is conjugated with glucuronic acid to form codeine-6-glucuronide, an active metabolite.
Directional10Codeine exhibits pH-dependent solubility, with highest solubility at acidic pH due to protonation of the tertiary amine group.
Single source11The N-demethylation pathway via CYP3A4 produces norcodeine, contributing less than 10% to overall metabolism.
Verified12Codeine's antitussive dose is 15-30 mg every 4-6 hours, distinct from its analgesic dose of 30-60 mg.
Verified13Plasma protein binding of codeine is low at 7%, allowing high free fraction for distribution.
Verified14Codeine O-demethylation to morphine shows 5-15% conversion rate, varying by CYP2D6 genotype.
Directional15The drug's logP (octanol-water partition coefficient) is 1.14, indicating moderate lipophilicity.
Single source16Codeine melts at 154-156°C and is stable under normal storage conditions away from light.
Verified17Renal clearance of codeine accounts for 4-6 mL/min, with most excretion as metabolites in urine.
Verified18Codeine has a potency ratio of 1:10 compared to morphine for analgesia due to partial conversion.
Verified19The phosphate salt form enhances aqueous solubility to 1 in 2.5 parts water at 25°C.
Directional20Codeine inhibits gastrointestinal motility via mu-receptor agonism in the enteric nervous system.
Single source21Ultra-rapid CYP2D6 metabolizers convert up to 30% of codeine to morphine, risking toxicity.
Verified22Codeine's Ki for mu-opioid receptor is 676 nM, lower affinity than morphine's 1.2 nM.
Verified23Steady-state plasma levels are achieved within 48 hours with repeated dosing every 4 hours.
Verified24Codeine sulfate has solubility of 293 mg/mL at 25°C, used for injectable formulations.
Directional25Hepatic first-pass effect reduces systemic exposure by metabolizing 40-50% of oral dose.
Single source26Codeine-6-glucuronide contributes to analgesia in poor CYP2D6 metabolizers.
Verified27The drug's chiral center at C6 allows for stereospecific metabolism to morphine.
Verified28Codeine exhibits linear pharmacokinetics over therapeutic doses of 15-60 mg.
Verified29Intramuscular bioavailability of codeine is nearly 100%, bypassing first-pass metabolism.
Directional30Codeine's CNS penetration is facilitated by its logBB value of 0.64.
Single source31Codeine is extracted from opium poppy Papaver somniferum, comprising 0.7-2.5% of total alkaloids.
VerifiedChemical and Pharmacological Properties Interpretation
A drug whose bitter taste is the least bitter thing about it, codeine’s whimsical metabolic lottery in our livers—where genetic luck dictates whether you get a weak painkiller, a decent cough suppressant, or a dangerous dose of morphine—proves that our chemistry is far more personal and consequential than its stable, crystalline powder suggests.
Legal Status and Epidemiology
1Codeine Schedule II in US since 2014 for combos >90mg/120ml.
Verified2Global codeine consumption 350 metric tons annually, led by Germany at 25% share.
Verified3Australia upscheduled codeine to prescription-only in Feb 2018, reducing dispensing by 50%.
Verified4US prescriptions: 12.5 million for codeine combos in 2021 per IQVIA.
Directional5Codeine banned in infants <12 years FDA black box warning 2017.
Single source6UK pharmacy sales of OTC codeine peaked at 17 million packs in 2007.
Verified7Canada rescheduled codeine to Schedule 1 in 2017, aligning with narcotics.
Verified8WHO consumption stats: morphine equivalent 0.8 mg/capita/day for codeine globally.
Verified9DEA quota for codeine 2023: 50,000 kg bulk finished dosage units.
Directional10France OTC limit 20 mg/tablet since 2020, sales dropped 30%.
Single source11Pediatric contraindication extended to <18 post-tonsillectomy by EMA 2015.
Verified12India regulates codeine under NDPS Act, requiring prescription, 1.2% prevalence misuse.
Verified13New Zealand banned OTC codeine >5mg in 2019, ED visits fell 20%.
Verified14Lifetime exposure epidemiology: 8.5% US adults per NSDUH 2021.
Directional15Codeine export controls tightened by INCB, 15% illicit diversion intercepted 2022.
Single source16Russia classifies codeine as Schedule II, pharmacy sales restricted since 2012.
Verified17Dispensing trends US: codeine/APAP scripts down 70% since 2012 peak.
Verified18Mexico OTC sales contribute to 25% of North American diversion.
Verified19EU harmonized scheduling: codeine exempt from Rx if <12.8mg with caffeine.
Directional20Opioid stewardship programs reduced codeine use by 40% in hospitals 2016-2020.
Single sourceLegal Status and Epidemiology Interpretation
The world's relationship with codeine is a regulatory tug-of-war, where nations from Germany to Australia keep tightening the screws on this prodigiously prescribed prodrug, yet its global consumption remains stubbornly high, proving that managing this opioid is a perpetual game of whack-a-mole.
Medical Uses and Efficacy
1In postoperative pain, codeine 60 mg provides analgesia equivalent to 650 mg aspirin plus 60 mg codeine combinations show additive effects.
Verified2Codeine is effective as an antitussive at 10-20 mg doses, reducing cough frequency by 50-70% in acute cough.
Verified3In children over 12 years, codeine 1 mg/kg/day divided q4-6h relieves moderate pain post-tonsillectomy.
Verified4Codeine combined with paracetamol (30/500 mg) reduces dental pain scores by 40% within 1 hour in 70% of patients.
Directional5For chronic cough in COPD, codeine linctus 10 mg tds suppresses cough by 60% over placebo in randomized trials.
Single source6Codeine 15 mg suppresses opioid-induced pruritus in 50% of patients post-spinal anesthesia.
Verified7In metastatic cancer pain, codeine 120-240 mg/day as step 2 WHO ladder provides relief in 55% of patients.
Verified8Codeine phosphate 30 mg with ibuprofen 400 mg shows NNT of 2.0 for 50% pain relief in post-op pain.
Verified9Antidiarrheal efficacy: codeine 30 mg reduces stool frequency by 33% in acute diarrhea vs placebo.
Directional10In sickle cell crisis, codeine 1 mg/kg q4h reduces pain scores by 2.5 points on VAS in children.
Single source11Codeine eye drops 1% reduce ocular pain post-surgery by 45% compared to placebo.
Verified12For labor pain, codeine 60 mg IM provides moderate relief in 40% of women, lasting 4 hours.
Verified13Codeine in combination with aspirin (8/500 mg) has PID max of 1.2 on 4-point scale for postpartum pain.
Verified14In acute URI cough, codeine 20 mg q4h reduces cough bouts by 46% over 24 hours vs dextromethorphan.
Directional15Codeine 60 mg orally achieves TOTPAR of 9.5 in third molar extraction pain model.
Single source16For irritable bowel syndrome, codeine 15-30 mg qid controls diarrhea in 65% of responsive patients.
Verified17Pediatric dose for cough: 1 mg/kg/day divided q4-6h effective in 80% of cases under supervision.
Verified18Codeine with acetaminophen (30/300 mg) provides 50% pain relief in 52% of osteoarthritis patients.
Verified19In migraine, codeine 30 mg + caffeine 100 mg reduces headache severity by 55% at 2 hours.
Directional20Codeine linctus 15 mg/5mL dosed 5-10 mL tds suppresses nocturnal cough in 70% of children >6 years.
Single source21For biliary colic, codeine 60 mg IM relieves pain in 60% of patients within 30 minutes.
Verified22Codeine 20 mg reduces postoperative nausea via antitussive effect in 45% of cases.
Verified23In rheumatoid arthritis flare, codeine 30 mg q6h adjunctively improves pain by 30% on VAS.
Verified24Codeine phosphate suppositories 30 mg provide analgesia in 50% of patients unable to take oral meds.
Directional25Combined with tramadol, codeine enhances analgesia in chronic back pain by 25% synergistically.
Single source26For dysmenorrhea, codeine 60 mg reduces pain scores by 3.2 on 10-point scale vs placebo.
Verified27Codeine 15 mg q4h effective for traveler's diarrhea, reducing episodes by 50% in 48 hours.
Verified28In neuropathic pain, codeine shows limited efficacy with <20% response rate at 180 mg/day.
Verified29Codeine 30 mg with promethazine enhances sedation and antitussive effect in perioperative setting.
Directional30For acute otitis media pain in children, codeine 1 mg/kg provides relief comparable to ibuprofen.
Single sourceMedical Uses and Efficacy Interpretation
Codeine appears to be a reasonably versatile workhorse of moderate potency, threading a narrow but surprisingly busy therapeutic needle where it reliably does a little bit of a lot of things—from muffling coughs to taking the edge off various pains—but rarely in a spectacularly potent or single-handed fashion.
Side Effects and Adverse Reactions
1Codeine causes constipation in 10-15% of users at analgesic doses, more frequent at >120 mg/day.
Verified2Drowsiness occurs in 20-25% of patients taking codeine 60 mg, dose-related sedation.
Verified3Nausea and vomiting reported in 5-10% of codeine users, mitigated by antiemetics.
Verified4Respiratory depression risk increases at doses >200 mg/day, with RR drop of 20% in sensitive patients.
Directional5Dizziness affects 10-15% of patients, leading to 2-3% discontinuation rates.
Single source6Pruritus occurs in 1-5% of codeine recipients, histamine-mediated.
Verified7Hepatotoxicity rare but reported with codeine-acetaminophen combos exceeding 4g APAP/day.
Verified8Orthostatic hypotension in 3-5% due to histamine release and vasodilation.
Verified9Urinary retention incidence 1-2% in males, higher with BPH comorbidity.
Directional10Allergic reactions including rash in <1%, anaphylaxis extremely rare 0.01%.
Single source11Miosis (pupil constriction) in 80% of users due to mu-opioid agonism.
Verified12Dry mouth reported in 5% of chronic users, dose-dependent xerostomia.
Verified13Sweating and flushing in 2-4% from peripheral opioid effects.
Verified14Seizures rare <0.1%, associated with overdose or CYP interactions.
Directional15Pancreatitis risk elevated 2-fold with chronic opioid use including codeine.
Single source16Hypogonadism in long-term users, reducing testosterone by 20-30% in males.
Verified17Neonatal respiratory depression in 10% of exposed infants if mother used near term.
Verified18Serotonin syndrome risk with SSRIs, incidence 0.1-1% polypharmacy.
Verified19Biliary spasm causing pain in 1% of cholecystitis patients.
Directional20Thrombocytopenia reported in <0.5% with prolonged use.
Single source21Adrenal insufficiency in chronic high-dose users, cortisol suppression up to 50%.
Verified22Cognitive impairment, reaction time slowed by 15% at 60 mg dose.
Verified23QT prolongation rare, <1% but monitor with cardiac history.
Verified24Myoclonus in overdose, 5-10% of severe cases.
Directional25Amenorrhea in 10-20% of premenopausal women on chronic opioids.
Single source26Osteoporosis risk increased 1.5-fold with >1 year use.
Verified27Delirium in elderly, 5% incidence at standard doses.
Verified28Hyperalgesia develops in 8% after 1 month continuous use.
Verified29Itching intensity peaks at 2-4 hours post-dose in 3%.
Directional30Fatigue reported by 15-20% at initiation of therapy.
Single source31Appetite suppression leading to weight loss 2-5 kg over 3 months in 10%.
VerifiedSide Effects and Adverse Reactions Interpretation
Codeine, in short, is an impressively versatile drug: while it diligently narrows your pupils 80% of the time, it generously expands your medical chart with a vast menu of possible side effects, ensuring your pain is traded for a complex new set of potential problems.
Sources & References
- Reference 1ACCESSDATAaccessdata.fda.govVisit source
- Reference 2PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4DRUGSdrugs.comVisit source
- Reference 5RXLISTrxlist.comVisit source
- Reference 6SIGMAALDRICHsigmaaldrich.comVisit source
- Reference 7PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 8FDAfda.govVisit source
- Reference 9PHARMGKBpharmgkb.orgVisit source
- Reference 10USPusp.orgVisit source
- Reference 11GUIDETOPHARMACOLOGYguidetopharmacology.orgVisit source
- Reference 12COCHRANELIBRARYcochranelibrary.comVisit source
- Reference 13UPTODATEuptodate.comVisit source
- Reference 14NEJMnejm.orgVisit source
- Reference 15AAFPaafp.orgVisit source
- Reference 16NICEnice.org.ukVisit source
- Reference 17WWWNCwwwnc.cdc.govVisit source
- Reference 18CDCcdc.govVisit source
- Reference 19DEAdea.govVisit source
- Reference 20NIDAnida.nih.govVisit source
- Reference 21TGAtga.gov.auVisit source
- Reference 22SAMHSAsamhsa.govVisit source
- Reference 23GOVgov.ukVisit source
- Reference 24FEDERALREGISTERfederalregister.govVisit source
- Reference 25INTERNATIONALNARCOTICSCONTROLBOARDinternationalnarcoticscontrolboard.orgVisit source
- Reference 26IQVIAiqvia.comVisit source
- Reference 27CANADAcanada.caVisit source
- Reference 28WHOwho.intVisit source
- Reference 29ANSMansm.sante.frVisit source
- Reference 30EMAema.europa.euVisit source
- Reference 31NCMncm.nic.inVisit source
- Reference 32MEDSAFEmedsafe.govt.nzVisit source
- Reference 33INCBincb.orgVisit source
- Reference 34UNODCunodc.orgVisit source
- Reference 35ECec.europa.euVisit source
- Reference 36AHAaha.orgVisit source